Contrasting MDxHealth (NASDAQ:MDXH) & SOPHiA GENETICS (NASDAQ:SOPH)

MDxHealth (NASDAQ:MDXH) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.

Institutional and Insider Ownership

31.6% of SOPHiA GENETICS shares are owned by institutional investors. 1.7% of MDxHealth shares are owned by insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

MDxHealth has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500. Comparatively, SOPHiA GENETICS has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500.

Profitability

This table compares MDxHealth and SOPHiA GENETICS’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MDxHealth	-31.07%	-1,078.01%	-21.71%
SOPHiA GENETICS	-44.48%	-62.74%	-21.85%

Analyst Ratings

This is a summary of recent ratings and price targets for MDxHealth and SOPHiA GENETICS, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MDxHealth	1	0	4	0	2.60
SOPHiA GENETICS	1	0	2	0	2.33

MDxHealth presently has a consensus target price of $7.75, suggesting a potential upside of 314.44%. SOPHiA GENETICS has a consensus target price of $7.50, suggesting a potential upside of 61.99%. Given MDxHealth’s stronger consensus rating and higher possible upside, equities research analysts plainly believe MDxHealth is more favorable than SOPHiA GENETICS.

Valuation & Earnings

This table compares MDxHealth and SOPHiA GENETICS”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MDxHealth	$107.88 million	0.86	-$33.52 million	($0.67)	-2.79
SOPHiA GENETICS	$77.27 million	4.10	-$79.00 million	($0.52)	-8.90

MDxHealth has higher revenue and earnings than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Summary

MDxHealth beats SOPHiA GENETICS on 9 of the 14 factors compared between the two stocks.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.